Jose M. Trevejo - 01 Feb 2022 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Leonard M. Greenstein
Issuer symbol
TARS
Transactions as of
01 Feb 2022
Net transactions value
$0
Form type
4
Filing time
03 Feb 2022, 16:36:41 UTC
Next filing
10 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Employee Stock Option (right to buy) Award $0 +116,424 $0.000000 116,424 01 Feb 2022 Common Stock 116,424 $20.64 Direct F1
transaction TARS Restricted Stock Units Award $0 +30,197 $0.000000 30,197 01 Feb 2022 Common Stock 30,197 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the option shares shall vest on February 1, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.